Berenberg reiterates Buy rating on Sanofi stock, citing improved pipeline returns

Multiple financial firms have issued positive assessments of Sanofi, with Berenberg reiterating a Buy rating and EUR110 price target due to improved drug pipeline returns and dispelled R&D skepticism, while Morgan Stanley upgraded to Overweight ($58 target) and Jefferies reiterated a Buy, citing organic growth potential and safety advantages. These endorsements are supported by InvestingPro's undervaluation assessment and a 3.5% dividend yield, alongside Sanofi's announcement to expand its insulin savings program to include commercially insured and Medicare patients from January 2026, potentially enhancing market access.

Analysis

Sanofi (SNY) has received a string of positive analyst assessments, signaling a strengthening investment thesis. Berenberg reiterated its Buy rating with a EUR110.00 price target, highlighting that the company's 2020 drug pipeline is already generating a 10% return, with the 2025 cohort forecast at 7%. The firm argues that investor skepticism over R&D productivity has unduly punished the stock, a viewpoint supported by InvestingPro's analysis of undervaluation. This bullish outlook is further reinforced by Morgan Stanley's upgrade to Overweight with a $58.00 target, citing potential for organic growth and margin improvement. Specific pipeline assets are driving this optimism, including positive Phase 2 data for immunology candidate brivekimig and the potential for peak sales of amlitelimab and frexalimab to significantly lift returns. Jefferies' Buy reiteration points to a competitive advantage, noting the favorable safety profile of its OX40L-targeting treatment. Beyond the pipeline, Sanofi’s fundamentals appear solid, evidenced by a 3.5% dividend yield and acknowledgement of top-tier sales growth through 2030. The company is also making strategic commercial moves, such as expanding its Insulins Valyou Savings Program to all U.S. patients for a $35 monthly cap starting January 2026, which is poised to broaden market access.

Key Decisions for Investors

• Given the consensus of positive analyst ratings from Berenberg, Morgan Stanley, and Jefferies, coupled with an 'undervalued' assessment, investors may consider the stock favorably for a long position.
• Monitor clinical trial results and regulatory updates for key pipeline assets, particularly amlitelimab, frexalimab, and duvakitug, as their success is a central pillar of the bull case for re-rating.
• For income-focused portfolios, the 3.5% dividend yield offers a supportive return while the growth thesis, predicated on pipeline execution and margin improvement, materializes.
• Note the long-term nature of several catalysts, such as the 2026 insulin program expansion and the 2030 sales growth outlook, suggesting the investment thesis requires a patient, multi-year perspective.